SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+0.02%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$697M
AUM Growth
+$61.6M
(+9.7%)
Cap. Flow
+$121M
Cap. Flow
% of AUM
17.37%
Top 10 Holdings %
Top 10 Hldgs %
45.13%
Holding
90
New
22
Increased
24
Reduced
17
Closed
14
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.3
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$29.7M |
| 2 |
Waystar Holding Corp
WAY
|
+$27.3M |
| 3 |
Corcept Therapeutics
CORT
|
+$25.2M |
| 4 |
Icon
ICLR
|
+$24.5M |
| 5 |
Maximus
MMS
|
+$21.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$47.4M |
| 2 |
Sanofi
SNY
|
+$34.1M |
| 3 |
Celcuity
CELC
|
+$30.9M |
| 4 |
Zimmer Biomet
ZBH
|
+$29.6M |
| 5 |
Kenvue
KVUE
|
+$25.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.44% |
| 2 | Industrials | 7.07% |
| 3 | Miscellaneous | 0.49% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Maximus
MMS
$3.02B
| $49.3M | 7.07% |
768,825
+268,521
| +54% | +$21.8M |
2024 Q3
6 quarters
|
|
|
2
Waystar Holding Corp
WAY
$5.15B
| $39.6M | 5.68% |
1,642,236
+1,028,511
| +168% | +$27.3M |
2025 Q4
1 quarter
|
|
|
3
Icon
ICLR
$13B
| $33.9M | 4.86% |
306,358
+179,156
| +141% | +$24.5M |
2025 Q4
1 quarter
|
|
|
4
Cencora
COR
$64.2B
| $31.7M | 4.55% |
100,894
+84,994
| +535% | +$29.7M |
2025 Q4
1 quarter
|
|
5
Dianthus Therapeutics
DNTH
$4.18B
| $31.1M | 4.45% |
370,045
-104,458
| -22% | -$6.05M |
2025 Q1
4 quarters
|
|
6
Anteris Technologies
AVR
$610M
| $29.9M | 4.28% |
5,382,965
+3,508,324
| +187% | +$20.2M |
2024 Q4
5 quarters
|
|
|
7
Corcept Therapeutics
CORT
$12.6B
| $27.2M | 3.9% |
+674,759
| New | +$25.2M |
2026 Q1
0 quarters
|
|
8
LivaNova
LIVN
$4.19B
| $26.8M | 3.84% |
421,615
+99,233
| +31% | +$6.4M |
2025 Q4
1 quarter
|
|
9
Tyra Biosciences
TYRA
$1.29B
| $23.2M | 3.33% |
605,439
+79,437
| +15% | +$2.57M |
2024 Q1
8 quarters
|
|
|
10
Celcuity
CELC
$2.93B
| $22.1M | 3.17% |
193,843
-283,224
| -59% | -$30.9M |
2025 Q3
2 quarters
|
|
11
GSK
GSK
$95.9B
| $21.3M | 3.05% |
+385,879
| New | +$20.9M |
2026 Q1
0 quarters
|
|
12
ANI Pharmaceuticals
ANIP
$1.61B
| $20.4M | 2.93% |
265,543
+178,271
| +204% | +$13.9M |
2024 Q4
5 quarters
|
|
13
Abbott
ABT
$178B
| $19.2M | 2.75% |
+186,574
| New | +$21.1M |
2026 Q1
0 quarters
|
|
14
Embecta
EMBC
$350M
| $16.3M | 2.34% |
+1,847,850
| New | +$19.3M |
2026 Q1
0 quarters
|
|
15
Abivax
ABVX
$7.68B
| $15.1M | 2.17% |
135,800
+92,676
| +215% | +$11M |
2025 Q4
1 quarter
|
|
16
Vir Biotechnology
VIR
$1.76B
| $13.4M | 1.93% |
1,498,620
+1,020,277
| +213% | +$8.13M |
2024 Q4
5 quarters
|
|
17
Haemonetics
HAE
$5.51B
| $12.4M | 1.78% |
220,672
+128,041
| +138% | +$8.34M |
2025 Q3
2 quarters
|
|
18
Sionna Therapeutics
SION
$185M
| $11.8M | 1.69% |
+294,340
| New | +$11.2M |
2026 Q1
0 quarters
|
|
|
19
Sanofi
SNY
$95.3B
| $11.5M | 1.66% |
239,671
-732,015
| -75% | -$34.1M |
2025 Q2
3 quarters
|
|
20
Rapport Therapeutics
RAPP
$1.36B
| $11.5M | 1.65% |
366,809
+181,544
| +98% | +$5.11M |
2025 Q3
2 quarters
|
|
21
Teleflex
TFX
$5.22B
| $11.3M | 1.63% |
94,800
+7,924
| +9% | +$874K |
2025 Q3
2 quarters
|
|
22
BioMarin Pharmaceuticals
BMRN
$10.7B
| $11M | 1.57% |
194,226
-38,462
| -17% | -$2.24M |
2025 Q1
4 quarters
|
|
23
DELISTED
Cross Country Healthcare
CCRN
| $10.3M | 1.48% |
1,098,393
+29,572
| +3% | +$265K |
2025 Q4
1 quarter
|
|
24
Protara Therapeutics
TARA
$147M
| $10.3M | 1.47% |
1,969,839
+254,445
| +15% | +$1.51M |
2025 Q4
1 quarter
|
|
25
Structure Therapeutics
GPCR
$1.56B
| $10.1M | 1.45% |
209,093
+7,593
| +4% | +$520K |
2025 Q4
1 quarter
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Sio Capital Management held 90 positions worth $697M, up 9.7% from $636M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Sio Capital Management deployed $121M of net new capital in Q1 2026, opening 22 new positions and adding to 24 existing holdings. Its largest new stake was Corcept Therapeutics: 674,759 shares worth $27.2M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 84% a quarter earlier, followed by Industrials and Miscellaneous.
On the sell side, the largest reduction was Sanofi, an estimated $34.1M trimmed.
- Sio Capital Management's largest Q1 2026 buy was Corcept Therapeutics: 674,759 shares worth $27.2M.
- Sio Capital Management added most to Cencora in Q1 2026, an estimated $29.7M increase.
- Sio Capital Management's biggest Q1 2026 reduction was Sanofi, cutting an estimated $34.1M.
- Sio Capital Management fully exited Cigna in Q1 2026, selling an estimated $47.4M.
- Sio Capital Management's ten largest holdings make up 45% of its $697M portfolio in Q1 2026.
- Sio Capital Management opened 22 new positions and closed 14 in Q1 2026.
- Sio Capital Management's portfolio value rose 9.7% quarter-over-quarter to $697M.
Based on Sio Capital Management's 13F filing for Q1 2026, filed 14 May 2026.